Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
standardized turmeric root extract · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | standardized turmeric root extract |
| Name | Type | Description |
|---|---|---|
| standardized turmeric root extract | DRUG | 1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days |
Inclusion Criteria: * Male or female 18 - 40 years of age. * Documented history of being homozygous for ΔF508 CFTR genotype. * Able to perform spirometry maneuvers, and have a forced expiratory volume at 1 second (FEV1) greater than or equal to 30% of predicted normal for age, gender, and height (K...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | VX-121/TEZ/D-IVA |
| Sionna Therapeutics, Inc. | SION | 2 | PHASE2 | SION-719 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
Standardized turmeric root extract is being investigated for use in cystic fibrosis. It is a small molecule being developed by Seer, Inc. (NASDAQ: SEER). The extract has completed a Phase 1 clinical trial in adult subjects with cystic fibrosis, though it remains investigational and is not approved.
Standardized turmeric root extract is a small molecule being studied in cystic fibrosis. The specific molecular target has not been disclosed. The extract is being evaluated for safety in adult patients with cystic fibrosis, and the completed Phase 1 trial was biomarker-selected, indicating a biological marker was used to guide the study.
Standardized turmeric root extract is being developed by Seer, Inc., a company traded on NASDAQ under the ticker SEER. The company is conducting clinical research on the extract as a potential treatment for cystic fibrosis. The extract is currently in early-stage clinical development.
Standardized turmeric root extract is in Phase 1 clinical development for cystic fibrosis. A Phase 1 safety study has been completed, but the drug is still investigational and has not been approved by regulatory authorities. The completed trial enrolled 11 adult participants in the United States.
Standardized turmeric root extract has one completed clinical trial, NCT00219882, titled "Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis." This Phase 1 study enrolled 11 adults with cystic fibrosis in the United States. The trial was uncontrolled, not randomized, and not double-blinded.
Standardized turmeric root extract is related to curcuminoids, as indicated by the completed clinical trial NCT00219882, which studied orally administered curcuminoids. However, the extract itself is a distinct formulation being developed by Seer, Inc. The trial evaluated the safety of this extract in adults with cystic fibrosis.